- Home
- HUMA vs SOR Comparison
HUMA vs SOR Comparison
Compare HUMA & SOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUMA
- SOR
- Stock Information
- Founded
- HUMA 2004
- SOR 1968
- Country
- HUMA United States
- SOR United States
- Employees
- HUMA N/A
- SOR N/A
- Industry
- HUMA Biotechnology: Pharmaceutical Preparations
- SOR Investment Managers
- Sector
- HUMA Health Care
- SOR Finance
- Exchange
- HUMA Nasdaq
- SOR Nasdaq
- Market Cap
- HUMA 427.2M
- SOR 348.7M
- IPO Year
- HUMA N/A
- SOR N/A
- Fundamental
- Price
- HUMA $1.28
- SOR $40.32
- Analyst Decision
- HUMA Strong Buy
- SOR
- Analyst Count
- HUMA 6
- SOR 0
- Target Price
- HUMA $14.60
- SOR N/A
- AVG Volume (30 Days)
- HUMA 5.7M
- SOR 16.2K
- Earning Date
- HUMA 05-09-2025
- SOR 01-01-0001
- Dividend Yield
- HUMA N/A
- SOR 7.24%
- EPS Growth
- HUMA N/A
- SOR N/A
- EPS
- HUMA N/A
- SOR 6.50
- Revenue
- HUMA N/A
- SOR N/A
- Revenue This Year
- HUMA N/A
- SOR N/A
- Revenue Next Year
- HUMA $1,217.58
- SOR N/A
- P/E Ratio
- HUMA N/A
- SOR $6.41
- Revenue Growth
- HUMA N/A
- SOR N/A
- 52 Week Low
- HUMA $1.18
- SOR $36.41
- 52 Week High
- HUMA $9.97
- SOR $42.75
- Technical
- Relative Strength Index (RSI)
- HUMA 20.12
- SOR 24.95
- Support Level
- HUMA $1.31
- SOR $41.27
- Resistance Level
- HUMA $3.36
- SOR $42.28
- Average True Range (ATR)
- HUMA 0.21
- SOR 0.81
- MACD
- HUMA -0.11
- SOR -0.19
- Stochastic Oscillator
- HUMA 0.24
- SOR 24.29
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.